D-0001-2021 Class II Terminated

Recalled by Strides Inc. — Lambertville, NJ

FDA drug recall D-0001-2021 was initiated by Strides Inc. on Aug 24, 2020 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Jan 11, 2022). Affected quantity: 11,280 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 7, 2020
Initiation Date
Aug 24, 2020
Termination Date
Jan 11, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,280 bottles

Product description

Strides Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg) 100 Tablets Rx Only Manufactured by: Strides Pharma Science Limited Bengaluru -562106 India Distributed by: Strides Pharma Inc., East Brunswick NJ 08816 NDC 64380-860-06

Reason for recall

Failed Dissolution Specifications

Distribution pattern

nationwide

Code information

7240675A; Exp. 12/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0001-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0001-2021. Report a data issue: hello@regdatalab.com.